ISTH Podcasts

As the treatment landscape for immune thrombocytopenia (ITP) continues to evolve, emerging therapies are offering new possibilities for patients and clinicians. Global expert Dr. Adam Cuker and patient advocate Cass Benedetto discuss the future of ITP treatment from both clinical and patient perspectives, from emerging therapies and unmet patient needs to individualized treatment decisions and the importance of considering quality of life beyond platelet counts. This episode is supported by Novartis.  See the following links to obtain credits for this CME activity: Syllabus: https://www.francefoundation.com/9499-itp-podcast-cme Podcast evaluation: https://surveys.francefoundation.com/s3/9499-Preparing-for-What-s-Next-for-ITP-Therapies-Enduring-Podcast-Evaluation

What happens when patients become partners in shaping clinical research? In this episode of the ISTH Pulse Podcast, host Dr. Julia Sandrin Gauer is joined by Dr. Sudeep Shivakumar and patient advocate Carol West to explore the role of patient perspectives in the EPCAT III trial, a Canadian-led study examining strategies to prevent venous thromboembolism (VTE) following hip and knee replacement surgery. The discussion highlights the collaboration between the EPCAT III research team and the CanVECTOR Patient Partners Platform, exploring how lived experiences can inform research priorities, trial design and clinical decision-making. Tune in to learn why bringing the patient voice into research matters and how meaningful collaboration can help shape future studies. Read the study here: www.nejm.org/doi/abs/10.1056/NEJMoa2603649?referrer=https%3A%2F%2Fwww.google.com%2F

Women can face unique blood clot risks across different stages of life, from hormonal contraception and pregnancy to the postpartum period and menopause. But there are still gaps in recognition and diganosis. In a special World Thrombosis Day episode of the ISTH Pulse Podcast, host Dr. Geoffrey Barnes is joined by experts Dr. James Douketis and Dr. Angela Weyand to ask an important question: Are we missing the warning signs? Together, they discuss where progress has been made, where gaps remain and what healthcare professionals can do to better recognize and address thrombosis risks in women. The conversation also explores broader challenges in women’s health, opportunities to improve research and clinical care and why this topic is at the center of the World Thrombosis Day campaign. Learn more and find resources at: https://www.worldthrombosisday.org/women-blood-clots/

In episode 3 of this ISTH Pulse Podcast miniseries, experts explore why next-generation mimetic therapies may be needed in hemophilia A and what they could add to an already evolving treatment landscape. The discussion examines how well current prophylactic options control bleeding, where treatment burden and unmet needs remain and whether less-frequent, subcutaneous dosing could support greater treatment convenience, adherence and access. Our experts also considers how factor VIII inhibitor status may influence treatment decisions and which patients could potentially benefit most as new mimetic therapies continue to develop. This episode is supported by an independent medical education grant from Bayer.

In the second episode of a special ISTH Pulse Podcast miniseries, experts explore why next-generation factor mimetics are being developed for hemophilia A and what unmet needs they may help address. The discussion examines the effectiveness of current prophylactic options, ongoing treatment burden and the potential role of less frequent, subcutaneous therapies in supporting treatment adherence and access. The episode also considers how factor VIII inhibitor status may influence treatment needs and what emerging factor mimetics could mean for the evolving hemophilia treatment landscape. This episode is supported by an independent medical education grant from Bayer.

In this first episode of a special ISTH Pulse Podcast miniseries, the discussion explores why next-generation mimetic therapies may be needed and where current treatment approaches may still leave gaps. The conversation examines whether existing prophylaxis provides adequate bleeding control, how treatment burden and less-frequent subcutaneous dosing may affect adherence and access and how factor VIII inhibitor status can influence treatment decisions. Tune in for a focused look at the evolving therapeutic landscape and the considerations shaping future approaches to hemophilia care. This episode is supported by an independent medical education grant from Bayer.

In this episode of the ISTH Pulse Podcast, host Julia Sandrin Gauer is joined by Dr. Sanjay Ahuja and Dr. Allison Wheeler to discuss the evolving landscape of factor mimetics for hemophilia A. They explore emerging therapies including Mim8, NXT007 and Inno8, the unmet needs that remain despite advances with emicizumab and factor replacement therapy, and what next-generation approaches could mean for the future of hemophilia care. The conversation also covers dosing, efficacy, safety, treatment switching and the patient populations that may benefit most as new therapeutic options continue to emerge. See a full transcript of this episode here: https://cdn.ymaws.com/www.isth.org/resource/resmgr/2026/transcript_for_podcast_1_sep.pdf

In this special episode of the ISTH Pulse Podcast, presented in collaboration with the Vasculearn Network, host Julia Sandrin Gauer is joined by Dr. Christian Ruff and Dr. Rushad Patell to discuss GLP-1 receptor agonists and their potential relationship with venous thromboembolism (VTE). The conversation explores what current evidence tells us about GLP-1 therapies and clotting risk, including the possible roles of weight loss, cardiometabolic health and inflammation. Tune in to hear more about the differences across GLP-1 medications, dual GIP/GLP-1 receptor agonists, patient populations that may warrant additional consideration and important gaps in the existing research.

Artificial intelligence (AI) is rapidly moving from the research setting into everyday clinical care, offering new possibilities for risk prediction, clinical decision support, image analysis and more. But as AI becomes increasingly integrated into healthcare, an important question emerges: Who’s really in charge? In this episode of the ISTH Pulse Podcast, we explore the legal and ethical considerations surrounding the use of AI in clinical practice. From accountability and physician responsibility to patient safety and responsible decision-making, tune in for a timely conversation about navigating the opportunities, responsibilities and emerging challenges of using AI in thrombosis and hemostasis care.

Immune thrombocytopenia (ITP) is often defined by a low platelet count, but its impact extends far beyond laboratory results. In this episode, Dr. Danny Hsu and Danielle Boyle discuss the latest findings from the global I-WISh 2.0 Study on patient and physician perceptions about ITP and explore ways to improve ITP patients’ quality of life. This episode is a must listen for people living with ITP and the physicians who care for them. Here are some additional resources to explore: https://onlinelibrary.wiley.com/doi/10.1002/ajh.70379 https://podcasts.apple.com/us/podcast/beyond-the-count/id1825045891